NHIC, Daewon poles apart on medicine negotiation

Published: 2008-07-31 06:58:00

Updated: 2008-07-31 06:58:00

The National Health Insurance Corporation and Daewon Pharm remain far apart in their negotiations over the price evaluation of home-grown Peluvi tablets (felubiprofen), new NSAID (nonsteroidal anti-inflammatory drug) for treatment of osteoarthritis.

Daewon is calling for a more “profitable'' price for promoting research and development of new drugs, while the NHIC is asking for something tha...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.